Kobayashi Pharma stock gains 1.69 percent on buyout proposal

Published on 10/04/2026 at 09:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kobayashi Pharma stock traded at JPY 7,107 on October 2, 2026, after the company disclosed a preliminary take-private proposal. Q2 revenue reached JPY 37.084 billion, while net income was JPY 100 million.

Kobayashi Pharma, JP3301100008, Illustration mit AI erstellt.

Kobayashi Pharma (ISIN JP3301100008) last traded at JPY 7,107 on the Tokyo Stock Exchange on October 2, 2026, up 1.69 percent from the prior close. The move followed a preliminary take-private proposal disclosed by the company on September 25, 2026, involving affiliates of NSSK and CVC Capital Partners.

Buyout proposal resets the valuation debate

Kobayashi Pharmaceutical said on September 25, 2026, that it had received a preliminary, nonbinding joint proposal from entities affiliated with Nippon Sangyo Suishin Kiko and CVC Capital Partners. The company described a potential take-private transaction as one possible measure to enhance corporate value.

Nippon.com reported on September 25, 2026, that the proposed transaction could value Kobayashi Pharmaceutical at JPY 500 billion. That figure compares with the stock's JPY 528.3 billion market capitalization on October 2, 2026, although the reported transaction value and the market value are not identical measures.

Q2 profit remains the key counterweight

Yahoo Finance lists fiscal Q2 2026 revenue at JPY 37.084 billion and earnings at JPY 100 million. The revenue scale gives the proposed transaction a clear operating base, while the slim earnings figure makes the quality of any restructuring plan central to the valuation discussion.

The market data add a second reference point. The October 2 price of JPY 7,107 stood JPY 115 below the 52-week high of JPY 7,222 and JPY 2,077 above the 52-week low of JPY 5,030, putting the share near the top of its annual range.

Stock stays near its yearly high

Kobayashi Pharma traded between JPY 6,933 and JPY 7,222 during the October 2 session, with volume of 580,800 shares. The combination of a 1.69 percent daily gain and a price near the 52-week high shows that the proposal has become the dominant valuation reference, while the Q2 net income figure keeps execution and governance reform in view.